Differentiate neurodegenerative diseases using saliva
- Trial ID
- NCT06869135
- Official Title
- Novel Method for Diagnosis of Neurodegenerative Diseases Based on Saliva Biochemical Profiling
- Goal
- Differentiate neurodegenerative diseases using saliva
- Status
- RECRUITING
- Sponsor
- Fondazione Don Carlo Gnocchi Onlus
- Study Type
- OBSERVATIONAL
- Enrollment
- 242 participants
- Conditions
- Neurodegenerative Diseases, Parkinson Disease, Alzheimer Disease, Parkinsonism, Mild Cognitive Impairment (MCI), Prodromal Parkinson's Disease
- Interventions
- Saliva collection, longitudinal
Plain-Language Summary
The goal is to find saliva-based biochemical markers that can help diagnose and distinguish Parkinson's, Alzheimer's, atypical parkinsonism, mild cognitive impairment, and even prodromal Parkinson's, so diagnosis could become easier and less invasive. The approach collects saliva samples over time and uses biochemical profiling to look for proteins, metabolites, or other molecules that reflect brain changes, offering a painless, repeatable way to complement or reduce the need for spinal fluid or imaging tests. They are enrolling adults 45 and older with diagnoses by standard criteria for PD, AD, atypical parkinsonism, prodromal PD, or MCI, who can consent and do not have active oral, infectious, oncological, or other systemic inflammatory diseases; PD participants should be on stable medication and not have vascular or drug-induced parkinsonism.
Locations
- IRCCS Don Gnocchi, Fondazione Don Gnocchi, Florence, FI, Italy
- Azienda Ospedaliero Universitaria Careggi Firenze, Florence, Italy
- IRCCS S. Maria Nascente, Fondazione Don Carlo Gnocchi ONLUS, Milan, Italy
- IRCCS Istituto Neurologico "Carlo Besta", Milan, Italy
- Centro S. Maria ai Servi, Fondazione Don Carlo Gnocchi Onlus, Parma, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Saliva collection, longitudinal. The goal is to find saliva-based biochemical markers that can help diagnose and distinguish Parkinson's, Alzheimer's, atypical parkinsonism, mild cognitive impairment, and even prodromal Parkinson's, so diagnosis could become easier and less invasive. The approach collects saliva samples over time and uses biochemical profiling to look for proteins, metabolites, or other molecules that reflect brain changes, offering a painless, repeatable way to complement or reduce the need for spinal fluid or imaging tests. They are enrolling adults 45 and older with diagnoses by standard criteria for PD, AD, atypical parkinsonism, prodromal PD, or MCI, who can consent and do not have active oral, infectious, oncological, or other systemic inflammatory diseases; PD participants should be on stable medication and not have vascular or drug-induced parkinsonism.
- Who can participate?
- Participants must be at least 45 Years.
- Where is this trial located?
- This trial is recruiting at 5 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 1 month.